• Disease
  • Faecal
  • Faecal Incontinence
  • Michael A Kamm

    Prominent publications by Michael A Kamm

    KOL Index score: 17231

    BACKGROUND & AIMS: Crohn's disease (CD) usually recurs after intestinal resection; postoperative endoscopic monitoring and tailored treatment can reduce the chance of recurrence. We investigated whether monitoring levels of fecal calprotectin (FC) can substitute for endoscopic analysis of the mucosa.

    METHODS: We analyzed data collected from 135 participants in a prospective, randomized, controlled trial, performed at 17 hospitals in Australia and 1 hospital in New Zealand, that assessed ...

    Also Ranks for: Surgery Patients |  fecal calprotectin |  6 months |  disease recurrence |  intestinal resection
    KOL Index score: 16351

    BACKGROUND & AIMS: SPD476 (MMX mesalamine), a novel, once-daily mesalamine formulation, uses MMX Multi Matrix System (MMX) technology to delay and extend delivery of active drug throughout the colon. We performed a randomized, double-blind, parallel-group, placebo-controlled, multicenter phase III study in patients with mild to moderately active ulcerative colitis.

    METHODS: Two hundred eighty patients with mild to moderately active ulcerative colitis received MMX mesalamine 2.4 g/day ...

    Also Ranks for: Mmx Mesalamine |  active ulcerative |  nonsteroidal colitis |  week patients |  sigmoidoscopy score
    KOL Index score: 16098

    The advent of biological therapy has revolutionized inflammatory bowel disease (IBD) care. Nonetheless, not all patients require biological therapy. Selection of patients depends on clinical characteristics, previous response to other medical therapy, and comorbid conditions. Availability, reimbursement guidelines, and patient preferences guide the choice of first-line biological therapy for luminal Crohn's disease (CD). Infliximab (IFX) has the most extensive clinical trial data, but ...

    Also Ranks for: Biological Therapy |  london position statement |  monoclonal antibodies |  ifx patients |  loss response
    KOL Index score: 16012

    BACKGROUND: Infliximab, a monoclonal antibody against tumor necrosis factor, is an effective maintenance therapy for patients with Crohn's disease without fistulas. It is not known whether infliximab is an effective maintenance therapy for patients with fistulas.

    METHODS: We performed a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy of infliximab maintenance therapy in 306 adult patients with Crohn's disease and one or more draining abdominal or ...

    Also Ranks for: Infliximab Maintenance Therapy |  patients response |  crohns disease fistulas |  placebo maintenance |  fistulizing crohn
    KOL Index score: 15672

    BACKGROUND & AIMS: Inflammatory bowel diseases (IBD) are becoming more common in Asia, but epidemiologic data are lacking. The Asia-Pacific Crohn's and Colitis Epidemiology Study aimed to determine the incidence and phenotype of IBD in 8 countries across Asia and in Australia.

    METHODS: We performed a prospective, population-based study of IBD incidence in predefined catchment areas, collecting data for 1 year, starting on April 1, 2011. New cases were ascertained from multiple ...

    Also Ranks for: Ibd Asia |  inflammatory bowel |  100000 individuals |  epidemiology study |  95 confidence interval
    KOL Index score: 14549

    BACKGROUND: Most patients with Crohn's disease need an intestinal resection, but a majority will subsequently experience disease recurrence and require further surgery. This study aimed to identify the optimal strategy to prevent postoperative disease recurrence.

    METHODS: In this randomised trial, consecutive patients from 17 centres in Australia and New Zealand undergoing intestinal resection of all macroscopic Crohn's disease, with an endoscopically accessible anastomosis, received 3 ...

    Also Ranks for: Intestinal Resection |  recurrence patients |  6 months |  randomised trial |  colonoscopy crohn
    KOL Index score: 14387

    BACKGROUND: Preliminary data suggest that short-term antibiotic therapy with a single drug is effective for the treatment of patients with pouchitis. However, some patients are resistant to treatment.

    AIM: To evaluate the therapeutic efficacy of a prolonged course of a combination of two antibiotics in patients with refractory or recurrent pouchitis, as well as its impact on their quality of life.

    METHODS: Patients with active refractory or recurrent pouchitis were recruited. This was ...

    Also Ranks for: Patients Pouchitis |  quality life |  metronidazole ciprofloxacin |  bowel disease |  activity score
    KOL Index score: 14361

    BACKGROUND & AIMS: Fecal microbiota transplantation (FMT) can induce remission in patients with ulcerative colitis (UC). In a randomized controlled trial of FMT in patients with active UC, we aimed to identify bacterial taxonomic and functional factors associated with response to therapy.

    METHODS: We performed a double-blind trial of 81 patients with active UC randomly assigned to groups that received an initial colonoscopic infusion and then intensive multidonor FMT or placebo enemas, 5 ...

    Also Ranks for: Patients Fmt |  ulcerative colitis |  fecal microbiota |  active uc |  specific bacteria
    KOL Index score: 14144

    BACKGROUND: The intestinal microbiota is implicated in the pathogenesis of ulcerative colitis. Faecal microbiota transplantation is a novel form of therapeutic microbial manipulation, but its efficacy in ulcerative colitis is uncertain. We aimed to establish the efficacy of intensive-dosing, multidonor, faecal microbiota transplantation in active ulcerative colitis.

    METHODS: We conducted a multicentre, double-blind, randomised, placebo-controlled trial at three hospitals in Australia. We ...

    Also Ranks for: Faecal Microbiota |  active ulcerative |  controlled trial |  randomised placebo |  endoscopic remission
    KOL Index score: 13954

    BACKGROUND & AIMS: To investigate the efficacy and safety of certolizumab pegol (a polyethylene-glycolated Fab' fragment of anti-tumor necrosis factor, CDP870) in Crohn's disease.

    METHODS: In a placebo-controlled, phase II study, 292 patients with moderate to severe Crohn's disease received subcutaneous certolizumab 100, 200, or 400 mg or placebo at weeks 0, 4, and 8. The primary end point was the percentage of patients with a clinical response at week 12 (a Crohn's Disease Activity ...

    Also Ranks for: Certolizumab Pegol |  placebo week |  patients clinical response |  polyethylene glycols |  adult antibodies
    KOL Index score: 13948

    Irritable Bowel Syndrome (IBS) is a common condition affecting around 10-20% of the population and associated with poorer psychological well-being and quality of life. The aim of the current study was to explore the efficacy of the Common Sense Model (CSM) using Structural Equation Modelling (SEM) in an IBS cohort. One hundred and thirty-one IBS patients (29 males, 102 females, mean age 38 years) participating in the IBSclinic.org.au pre-intervention assessment were included. Measures ...

    Also Ranks for: Visceral Sensitivity |  illness perceptions |  bowel syndrome |  symptom severity |  psychological distress
    KOL Index score: 13598

    BACKGROUND & AIMS: SPD476 (LIALDA in the US; MEZAVANT in the EU; otherwise known as MMX mesalamine; Shire Pharmaceuticals Inc., Wayne, PA, under license from Giuliani SpA, Milan, Italy) is a novel, once-daily, high-strength (1.2 g/tablet) formulation of mesalamine, utilizing MMX Multi Matrix System (MMX) technology designed to deliver the active drug throughout the colon. We performed a double-blind, multicenter study, comparing MMX mesalamine vs placebo for the treatment of active ...

    Also Ranks for: Mmx Mesalamine |  active ulcerative colitis |  day daily |  endoscopic remission |  8 weeks
    KOL Index score: 13096

    OBJECTIVES: To determine (i) risk factors in the development of third degree obstetric tears and (ii) the success of primary sphincter repair.

    DESIGN: (i) Retrospective analysis of obstetric variables in 50 women who had sustained a third degree tear, compared with the remaining 8553 vaginal deliveries during the same period. (ii) Women who had sustained a third degree tear and had primary sphincter repair and control subjects were interviewed and investigated with anal endosonography, ...

    Also Ranks for: Degree Tear |  primary repair |  anal sphincter |  obstetric labor complications |  pudendal nerve damage
    KOL Index score: 12991

    PURPOSE: The aim of lateral internal anal sphincterotomy when treating anal fissure is to divide the distal one-third to one-half of the internal anal sphincter. This study aimed to evaluate prospectively the extent of disruption to the internal anal sphincter following lateral anal internal sphincterotomy and also to establish the prevalence of symptoms of anal incontinence in these patients.

    METHODS: Fifteen patients with anal fissure (ten females and five males) had bowel symptoms ...

    Also Ranks for: Internal Anal |  lateral sphincterotomy |  sphincter division |  fecal incontinence |  surgical procedures
    KOL Index score: 12952

    PURPOSE: We employed the Common Sense Model (CSM) of illness perceptions to examine the relative contribution of illness perceptions, stoma self-efficacy, and coping strategies in explaining anxiety and depression symptoms in patients with a fecal ostomy. The CSM suggests that the consequences of illness activity, such as psychological distress, are influenced by an individual's illness perceptions as well as what coping strategies they engage in.

    DESIGN: Descriptive, cross-sectional ...

    Also Ranks for: Illness Perceptions |  coping strategies |  psychological morbidity |  anxiety depression |  patients stoma


    Michael A Kamm: Influence Statistics

    Sample of concepts for which Michael A Kamm is among the top experts in the world.
    Concept World rank
    behavioural treatment constipation #1
    delivery postpartum deterioration #1
    current bowel function #1
    autonomic gut #1
    r093877 healthy subjects #1
    5 parameters combination #1
    ileus chronic symptoms #1
    neurogenic faecal #1
    bisacodyltreated #1
    sacrum severity illness #1
    human colonic treatment #1
    week permanent stimulation #1
    operation prolapse repair #1
    gut immunological interactions #1
    nbi colitis #1
    sbm sps #1
    47 patients remission #1
    ibd fam #1
    recurrence thiopurine #1
    mmx matrix #1
    panca ibd patients #1
    mucosal healing duration #1
    treatment mmx mesalazine #1
    drugs success #1
    surgery stepup #1
    vaginal delivery eog #1
    61 months range #1
    disturbed gastric #1
    passive faecal incontinence #1
    cutoff depression #1
    laxative sodium picosulfate #1
    transsphincteric injection #1
    fmt crohn disease #1
    normal colonic transit #1
    higher prevalence amca #1
    internal sphincter endosonography #1
    multidonor intensive #1
    sigmoid colon specimens #1
    patients dilated rectum #1
    illness male manometry #1
    fecal incontinent episodes #1
    sonographic evidence trauma #1
    external sphincter outcome #1
    delivery late onset #1
    psa mmx mesalazine #1
    rectal mucosal blood #1
    crossover study sns #1
    purpose previous paper #1

    Key People For Faecal Incontinence

    Top KOLs in the world
    Michael A Kamm
    faecal incontinence ulcerative colitis inflammatory bowel disease
    Steven David Wexner
    rectal cancer fecal incontinence laparoscopic surgery
    Carolynne J Vaizey
    faecal incontinence sacral nerve stimulation tibial nerve
    Ralph John Nicholls
    restorative proctocolectomy faecal incontinence ulcerative colitis
    Ann C Lowry
    fecal incontinence subtotal colectomy stool consistency
    Robert D Madoff
    rectal cancer fecal incontinence prolonged thromboprophylaxis

    Michael A Kamm:Expert Impact

    Concepts for whichMichael A Kammhas direct influence:Faecal incontinence,  Ulcerative colitis,  Inflammatory bowel disease,  Fecal incontinence,  Sacral nerve stimulation,  Crohns disease,  Anal sphincter,  Idiopathic megarectum.

    Michael A Kamm:KOL impact

    Concepts related to the work of other authors for whichfor which Michael A Kamm has influence:Inflammatory bowel disease,  Ulcerative colitis,  Fecal incontinence,  Gut microbiota,  Chronic constipation,  Irritable bowel syndrome,  Colorectal cancer.



    Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

    The Austin Hospital, Gastroenterology, Melbourne, Australia | University of Melbourne, Department of Medicine, Parkville, Australia | University of Melbourne, Medicine, Melbourne, Australia | St Vincent’s Hospital Melbourne, Department of Gastroenter